Information  X 
Enter a valid email address

Diurnal Group PLC (DNL)

  Print      Mail a friend

Friday 11 September, 2020

Diurnal Group PLC

Shares and AJ Bell Investor Evening Webinar

RNS Number : 6718Y
Diurnal Group PLC
11 September 2020
 

11 September 2020

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Diurnal to present at Shares and AJ Bell Investor Evening Webinar

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be presenting at the Shares and AJ Bell investor evening webinar on Thursday 17 September 2020. The webinar will start at 18:00 BST and investors can register to attend here: https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-170920 .

 

Martin Whitaker, Chief Executive Officer of Diurnal, will be presenting an overview of the Company and will be available to take questions during the event.

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: Rupert Dearden




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRALMMFTMTMBBMM

a d v e r t i s e m e n t